中国在组织专利和研究领域领先,推动了全球疾病治疗和药物开发的进步。 China leads in organoid patents and research, driving global advances in disease treatment and drug development.

作为防治造成全球70%以上死亡的慢性疾病的关键工具,有机技术正在迅速发展,它创造了实验室培育的小型有机体。 Organoid technology, which creates lab-grown mini-organs, is advancing rapidly as a key tool in fighting chronic diseases responsible for over 70% of global deaths. 中国已成为有机物研究的全球领先者,在出版物中名列第二,在专利方面居领先地位,自2024年以来,中国政府给予了强有力的支持,包括对干细胞和稀有疾病药物开发的监管认可。 China has emerged as a global leader in organoid research, ranking second in publications and leading in patents, with strong government support including regulatory recognition for stem cell and rare disease drug development since 2024. 该国目前正根据《第十五五年计划》将工业化和一个国家生物库列为优先事项。 The country is now prioritizing industrialization and a national biobank under its 15th Five-Year Plan. 从全球来看,美国和英国发起了使使用有机物标准化的重大倡议,反映出减少动物试验和改善药物开发的势头日益增强。 Globally, the U.S. and U.K. have launched major initiatives to standardize organoid use, reflecting growing momentum in reducing animal testing and improving drug development.